JP2020517740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517740A5 JP2020517740A5 JP2020507722A JP2020507722A JP2020517740A5 JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5 JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- pharmaceutical composition
- domain
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023065903A JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901462 | 2017-04-21 | ||
| AU2017901462A AU2017901462A0 (en) | 2017-04-21 | Agents for treating or preventing motor neurone disease and uses therefor | |
| AU2018900762 | 2018-03-08 | ||
| AU2018900762A AU2018900762A0 (en) | 2018-03-08 | “agents for treating disease and uses therefor” | |
| PCT/AU2018/050357 WO2018191786A1 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Division JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517740A JP2020517740A (ja) | 2020-06-18 |
| JP2020517740A5 true JP2020517740A5 (https=) | 2021-05-27 |
Family
ID=63855469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507722A Pending JP2020517740A (ja) | 2017-04-21 | 2018-04-20 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200148780A1 (https=) |
| EP (1) | EP3612566A4 (https=) |
| JP (2) | JP2020517740A (https=) |
| KR (1) | KR20200015477A (https=) |
| CN (1) | CN110831975A (https=) |
| AU (1) | AU2018255489B2 (https=) |
| IL (2) | IL309046B2 (https=) |
| WO (1) | WO2018191786A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
| TWI809147B (zh) | 2018-07-13 | 2023-07-21 | 美商阿列克特有限責任公司 | 抗分揀蛋白抗體及其使用方法 |
| US20200392229A1 (en) * | 2019-06-11 | 2020-12-17 | Alector Llc | Methods of use of anti-sortilin antibodies |
| WO2021016601A1 (en) | 2019-07-25 | 2021-01-28 | Implicit Bioscience Limited | Methods and agents for treating acute neuroinflammatory injury |
| MX2022010006A (es) * | 2020-02-13 | 2022-09-19 | Prilenia Neurotherapeutics Ltd | Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. |
| WO2021253335A1 (zh) * | 2020-06-18 | 2021-12-23 | 深圳迈瑞生物医疗电子股份有限公司 | 抗可溶性cd14亚型抗体、试剂盒及其应用 |
| AU2021339468A1 (en) * | 2020-09-10 | 2023-03-30 | Implicit Bioscience Limited | Therapeutic methods and agents for the treatment of myocardial infarction |
| AU2021356298A1 (en) | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118290585B (zh) * | 2024-06-04 | 2024-08-30 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd14工程抗体及应用 |
| CN120399098B (zh) * | 2025-07-03 | 2025-09-16 | 上海玄言生物科技有限公司 | 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI920450A7 (fi) * | 1989-08-01 | 1992-01-31 | Scripps Clinic And Res Foundation | Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi |
| ATE335072T1 (de) | 1993-05-28 | 2006-08-15 | Scripps Research Inst | Methoden für inhibition der cd14-abhängigen zellaktivierung |
| EP0792162B1 (en) * | 1994-09-16 | 2005-11-09 | The Scripps Research Institute | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
| US7264967B2 (en) | 2000-11-22 | 2007-09-04 | Mochida Pharmaceutical Co., Ltd. | Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding |
| EP1819829A1 (en) | 2004-12-08 | 2007-08-22 | ICOS Corporation | Recombinant method for making multimeric proteins |
| US20090181008A1 (en) * | 2005-11-10 | 2009-07-16 | Satoris, Inc. | Methods of treating alzheimer's disease |
| KR101256837B1 (ko) * | 2009-03-09 | 2013-04-22 | 경북대학교 산학협력단 | 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도 |
| CA2789963C (en) * | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
-
2018
- 2018-04-20 EP EP18788123.0A patent/EP3612566A4/en active Pending
- 2018-04-20 US US16/606,727 patent/US20200148780A1/en not_active Abandoned
- 2018-04-20 CN CN201880040765.4A patent/CN110831975A/zh active Pending
- 2018-04-20 AU AU2018255489A patent/AU2018255489B2/en active Active
- 2018-04-20 JP JP2020507722A patent/JP2020517740A/ja active Pending
- 2018-04-20 KR KR1020197033198A patent/KR20200015477A/ko not_active Ceased
- 2018-04-20 WO PCT/AU2018/050357 patent/WO2018191786A1/en not_active Ceased
- 2018-04-20 IL IL309046A patent/IL309046B2/en unknown
- 2018-04-20 IL IL270097A patent/IL270097B2/en unknown
-
2021
- 2021-09-23 US US17/483,517 patent/US12297287B2/en active Active
-
2023
- 2023-04-13 JP JP2023065903A patent/JP2023090751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517740A5 (https=) | ||
| JP2016513682A5 (https=) | ||
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2019522961A5 (https=) | ||
| JP2020513791A5 (https=) | ||
| KR101649168B1 (ko) | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 | |
| JP2020517249A5 (https=) | ||
| JP2013500941A5 (https=) | ||
| JP2018512138A5 (https=) | ||
| JP2015530971A5 (https=) | ||
| JP2020536888A5 (https=) | ||
| JP2019054802A5 (https=) | ||
| JP2016508496A5 (https=) | ||
| JP2019110906A5 (https=) | ||
| JP2009519718A5 (https=) | ||
| JP2019505527A5 (https=) | ||
| JP2020502996A5 (https=) | ||
| JP2011514150A5 (https=) | ||
| JP2009540018A5 (https=) | ||
| JP2012504634A5 (https=) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| JP2015533795A5 (https=) | ||
| JP2016136963A5 (https=) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| JP2017223685A5 (https=) |